Profile: Esperion Therapeutics Inc (ESPR.OQ)
24 Jun 2016
Esperion Therapeutics, Inc., incorporated on January 22, 2008, is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company's segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company's lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins.
Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors. Bempedoic acid is converted to the coenzyme A (CoA) form in the liver, a required biochemical step for the inhibition of ACL, an enzyme upstream of Hydroxymethylglutaryl (HMG)-CoA reductase.
Esperion Therapeutics Inc
3891 RANCHERO DRIVE, SUITE 150
ANN ARBOR MI 48108